Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

Share Price is delayed by 15 minutes
Get Live Data
849.50    -28.50 (-3.25%)
Bid:
852.50
Ask:
854.50
Spread: 2.00 (0.235%)
Market Cap: £978.40m
KNOS Live PriceLast checked at - London Stock Exchange

Intraday Kainos Group Share Chart

Trading Update

6 Sep 2016 07:00

RNS Number : 0050J
Kainos Group plc
06 September 2016
 

 

ANNOUNCEMENT

6 September 2016

 

Kainos Group plc

("Kainos" or "the Group")

Trading Update

 

- Group maintains guidance for current year -

 

Kainos Group plc (KNOS), a leading UK-based provider of IT, consulting and software solutions, today issues a trading update for the period from 1 April 2016 to 31 August 2016.

 

In the Digital Services division, the Group is experiencing good growth in the public sector. Demand from central and regional government clients continues to strengthen, with notable new contract wins at the National Offender Management Service and the Home Office.

 

Demand for WorkSmart services is strong in the UK and mainland Europe, where the Group has added a number of new enterprise clients, including Tullett Prebon Group Limited. Take-up of the Group's SaaS-based automated testing product, Smart, is solid and the Group continues to invest in both product development and sales and marketing for Smart.

 

The Evolve division continues to make progress with its Integrated Care SaaS platform and has signed a five-year subscription agreement with Hygieia to use Evolve to power its insulin therapy navigation application which aims to help diabetics systematically manage their changing insulin requirements. In the UK, the Evolve for iPad™ offering, which allows clinicians to access electronic patient records on the move, is now in live operation at the South East Coast Ambulance Service. Market conditions in the NHS remain challenging, with limited additional funding to drive demand.

 

Although the outcome of the UK's referendum on Europe ('Brexit') brings with it some uncertainties, the Group continues to see immediate opportunities for growth.

 

Kainos has a robust balance sheet with strong reserves, no debt and strong cash generation, as well as a growing level of recurring revenue. The Group expects results for the full year to be in line with market expectations.

 

 

 

 

-ENDS-

 

For further information, please contact:

 

Kainos via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Brian Gannon, SVP Corporate Development

 

Investec Bank plc +44 20 7597 5970

Dominic Emery/Sebastian Lawrence

Patrick Robb/Matt Lewis

 

FTI Consulting LLP +44 20 3727 1000

Matt Dixon/Chris Lane

 

About Kainos

Kainos is a UK-based provider of IT services, consulting and software solutions. It specialises across multiple sectors in the development of digital technology solutions, including software design and agile software development. The Group's Evolve Electronic Medical Records (EMR) product provides a market-leading comprehensive suite of digital services to healthcare providers such as hospitals and community care organisations. Kainos has also developed an automated testing product, Smart, to complement its Workday implementation services.

 

Kainos Group plc (KNOS) is listed on the main market of the London Stock Exchange. At 31 March 2016, it had almost 800 staff working in eight offices in the USA, UK, Ireland, Poland and the Netherlands.

 

For further information please visit the company website: https://www.kainos.com/

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLAMFTMBBMBFF
Date   Source Headline
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTransaction in Own Shares
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 202612:45 pmRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
1st Dec 20259:27 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 202511:39 amRNSDirector/PDMR shareholdings
24th Nov 202511:22 amRNSNotification of Major Holdings
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:50 amRNSRenewal of Share Buyback Programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20252:57 pmRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 202512:49 pmRNSDirector / PDMR shareholdings
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20257:00 amRNSInterim results
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 202511:03 amRNSTotal Voting Rights
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.